journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Anticancer Therapy

journal
https://www.readbyqxmd.com/read/28787182/improving-postoperative-radiotherapy-following-radical-prostatectomy
#1
D Lipman, B R Pieters, Theo M de Reijke
Prostate cancer has one of the highest incidences in the world, with good curative treatment options like radiotherapy and radical prostatectomy. Unfortunately, about 30% of the patients initially treated with curative intent will develop a recurrence and need adjuvant treatment. Five randomized trials covered the role of postoperative radiotherapy after radical prostatectomy, but there is still a lot of debate about which patients should receive postoperative radiotherapy. Areas covered: This review will give an overview on the available literature concerning post-operative radiotherapy following radical prostatectomy with an emphasis on the five randomized trials...
August 8, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28780888/anti-gd2-immunotherapy-for-neuroblastomas
#2
Sameer Sait, Shakeel I Modak
Current therapeutic approaches for high-risk neuroblastoma (HR-NB) include high-dose chemotherapy, surgery and radiotherapy; interventions that are associated with long and short-term toxicities. Effective immunotherapy holds particular promise for improving survival and quality of life by reducing exposure to cytotoxic agents. GD2, a surface glycolipid is the most common target for immunotherapy. Areas covered: We review the status of anti-GD2 immunotherapies currently in clinical use for neuroblastomas and novel GD2-targeted strategies in preclinical development...
August 7, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28756722/the-role-of-novel-biomarker-he4-in-the-diagnosis-prognosis-and-follow-up-of-ovarian-cancer-a-systematic-review
#3
Giuseppe Scaletta, Francesco Plotti, Daniela Luvero, Stella Capriglione, Roberto Montera, Andrea Miranda, Salvatore Lopez, Corrado Terranova, Carlo De Cicco Nardone, Roberto Angioli
Ovarian cancer is the leading cause of death from gynecologic cancers, in fact, >80% of cases are diagnosed as advanced-stage disease associated with a high mortality rate (<40% of women cured). A systematic review was performed to estimate the role of HE4 in the diagnosis, prognosis and follow-up of ovarian tumors. Areas covered: A comprehensive search of the literature from January 1952 to August 2016 was conducted using the terms 'ovarian tumor' and 'ovarian cancer' combined with 'HE4' and 'human epididymis protein 4'...
August 3, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28737470/recent-advances-in-circulating-tumor-cells-and-cell-free-dna-in-metastatic-prostate-cancer-a-review
#4
Sunil Parimi, Jenny J Ko
The treatment landscape of metastatic prostate cancer has changed dramatically over the past five years. As new discoveries are made and further novel therapies become available, there is a heightened urgency to develop biomarkers that can guide prognoses and predict therapy responses. Circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) in the blood have emerged as potential promising tumor avatars. Areas covered: In this review, we describe technological breakthroughs and clinical implementation of the CTCs and ctDNA...
July 31, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28724330/immunotherapy-advances-for-mesothelioma-treatment
#5
Emyr Bakker, Alice Guazzelli, Firozeh Ashtiani, Constantinos Demonacos, Marija Krstic-Demonacos, Luciano Mutti
Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. Despite application of different modalities such as chemotherapy, radiotherapy and surgery, patient prognosis remains very poor and therapies are ineffective. Much research currently focuses on the application of novel approaches such as immunotherapy towards this disease. Areas covered: The types, stages and aetiology of mesothelioma are detailed, followed by a discussion of the current treatment options such as radiotherapy, surgery, and chemotherapy...
July 31, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28750593/the-role-of-external-beam-radiation-therapy-in-well-differentiated-thyroid-cancer
#6
Sarah N Hamilton, Eric Tran, Eric Berthelet, John Wu
dglkf Introduction: This review article explores the use of external beam radiotherapy (EBRT) in well differentiated thyroid cancer. Areas covered: The published literature on EBRT for advanced pT4 disease and macroscopic unresectable disease to improve locoregional control is reviewed. EBRT techniques, volumes and doses are discussed in detail. The potential acute and late toxicities of EBRT are discussed in the context of the published literature. The use of EBRT for patients with metastatic disease is also described...
July 28, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28715968/applications-of-hyperthermic-intraperitoneal-chemotherapy-for-metastatic-colorectal-cancer
#7
Matthias Hornung, Jens M Werner, Hans J Schlitt
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) plays a pivotal role in the current treatment of peritoneal carcinomatosis (PC) from colorectal cancer (CRC). Since the first demonstration, benefits for patients and especially an increase in survival have been described. In recent years, feasibility, efficacy and safety of HIPEC have been improved and progress has been made in understanding its oncological mechanism. Areas covered: In this article, leading publications have been reviewed including clinical trials to describe the clinical presentation of PC due to CRC and present recent evidence of the CRS/HIPEC procedure...
July 25, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28737065/postoperative-stereotactic-radiosurgery-for-limited-brain-metastases-are-we-ready-for-prime-time
#8
Simon S Lo, Paul D Brown, Matthew Foote, Samuel T Chao, Eric L Chang, Arjun Sahgal
No abstract text is available yet for this article.
July 24, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28705091/molecular-approaches-to-potentiate-cisplatin-responsiveness-in-carcinoma-therapeutics
#9
Aayushi Jain, Devashree Jahagirdar, Pritish Nilendu, Nilesh Kumar Sharma
Cisplatin has been considered as the crucial regimen of widely prescribed chemotherapy treatment for cancer. The advancing treatment of cancers has reached the border line, where tumors show resistance to cisplatin and may thwart its use. Other than issues of drug resistance, cisplatin has been reported to evince side effects such as nephrotoxicity and ototoxicity. Therefore, there is a compelling need to untangle the problems associated with cisplatin treatment in carcinoma. Areas covered: In this review, we summarize the current status of combinatorial options to bring about better pre-clinical and clinical cisplatin drug responses in carcinoma...
July 20, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28699811/fatigue-alopecia-and-stomatitis-among-patients-with-breast-cancer-receiving-cyclin-dependent-kinase-4-and-6-inhibitors-a-systematic-review-and-meta-analysis
#10
Shaimaa Lasheen, Kyrillus S Shohdy, Loay Kassem, Omar Abdel-Rahman
BACKGROUND: Cyclin-dependent kinase (CDK) inhibitors emerge as efficacious agents in hormone positive metastatic breast cancer with more acceptable toxicity profiles than cytotoxic chemotherapy. However, some adverse effects such as fatigue, alopecia and stomatitis, vastly concern patients. METHODS: The search was conducted in PubMed, American Society of Clinical Oncology meeting library, European Society for Medical Oncology meeting abstract, and the San Antonio meeting abstract databases...
July 20, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28701107/overcoming-resistance-to-egfr-tyrosine-kinase-inhibitors-in-lung-cancer-focusing-on-non-t790m-mechanisms
#11
Kenichi Suda, Christopher J Rivard, Tetsuya Mitsudomi, Fred R Hirsch
despite initial dramatic efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer patients, emergence of acquired resistance is almost inevitable. The EGFR T790M secondary mutation that accounts for ~50% of resistance is now treatable with osimertinib. However, for the remaining 50% of patients who develop resistance mechanisms other than T790M mutation, cytotoxic chemotherapies are still the standard of care and novel treatment strategies are urgently needed. Areas covered: In this review, we discuss current experimental and clinical evidence to develop better treatment strategies to overcome or prevent acquired resistance to EGFR-TKIs in lung cancers, focusing on non-T790M mechanisms...
July 17, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28656792/recent-advances-in-targeted-advanced-lung-cancer-therapy-in-the-elderly
#12
Tania Losanno, Cesare Gridelli
With increasing life expectancy over the last several decades, the incidence of lung cancer is increasing in the elderly population too. In clinical practice about 50% of lung cancers were diagnosed in patients older than 65 years and about 30-40% of lung cancer patients are 70 years old or more. Treatment of elderly patients with non-small-cell lung cancer (NSCLC) represents a challenge in clinical practice, because these patients are not eligible for aggressive therapies for the age-related reduction of functional reserve of many organs and comorbidities...
July 4, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28622054/down-regulation-of-liver-intestine-cadherin-enhances-noscapine-induced-apoptosis-in-human-colon-cancer-cells
#13
Xia Tian, Meng Liu, Qingxi Zhu, Jie Tan, Weijie Liu, Yanfen Wang, Wei Chen, Yanli Zou, Yishan Cai, Zheng Han, Xiaodong Huang
BACKGROUND: The aim of the present study was to explore the signaling pathway of noscapine which induces apoptosis by blocking liver-intestine cadherin (CDH17) gene in colon cancer SW480 cells. METHODS: Human colon cancer SW480 cells were transfected with CDH17 interference vector and treatment with 10 µmol/L noscapine. The proliferation and apoptosis of SW480 cells were detected by MTT assay and AnnexinV-FITC/PI flow cytometry kit (BD), respectively. Cell invasion were assessed by transwell assays...
June 27, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28618843/risk-of-cardiac-death-among-cancer-survivors-in-the-united-states-a-seer-database-analysis
#14
Omar Abdel-Rahman
 Background: Population-based data on the risk of cardiac death among cancer survivors are needed. This scenario was evaluated in cancer survivors (>5 years) registered within the Surveillance, Epidemiology and End Results (SEER) database. METHODS: The SEER database was queried using SEER*Stat to determine the frequency of cardiac death compared to other causes of death; and to determine heart disease-specific and cancer-specific survival rates in survivors of each of the 10 most common cancers in men and women in the SEER database...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28594258/first-line-chemotherapy-with-pemetrexed-plus-cisplatin-for-malignant-peritoneal-mesothelioma
#15
Eriko Fujimoto, Takashi Kijima, Kozo Kuribayashi, Yoshiki Negi, Shingo Kanemura, Koji Mikami, Hiroshi Doi, Kazuhiro Kitajima, Takashi Nakano
BACKGROUND: Mesothelioma of peritoneal origin has wider variation in treatment outcomes than mesothelioma of pleural origin, likely because peritoneal mesothelioma comprises borderline malignant variants and aggressive malignant peritoneal mesothelioma (MPeM). This study retrospectively evaluates the efficacy of first-line systemic pemetrexed and cisplatin chemotherapy in MPeM. RESEARCH DESIGN AND METHODS: Twenty-four patients with histologically proven MPeM were treated with pemetrexed plus cisplatin as a first-line systemic chemotherapy...
June 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28504011/the-future-of-oncology-therapeutics
#16
André Mansinho, Valentina Boni, María de Miguel, Emiliano Calvo
No abstract text is available yet for this article.
May 22, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28689438/the-cost-and-value-of-glioblastoma-therapy
#17
Daniel N Cagney, Brian M Alexander
No abstract text is available yet for this article.
August 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28657372/phthalocyanine-induced-phototherapy-coupled-with-doxorubicin-a-promising-novel-treatment-for-breast-cancer
#18
REVIEW
Eric Chekwube Aniogo, Blassan Plackal Adimuriyil George, Heidi Abrahamse
Globally, breast cancer is the most common life-threatening malignant disease among women. Adjuvant chemotherapeutic treatment of anthracycline-based chemotherapy (e.g., doxorubicin) has been shown to be more advantageous over non-anthracycline-based therapies, yet possess the tenacity of developing resistance and potential side effects which have limited its use in the clinical setting. These reasons necessitate combining doxorubicin with emerging photodynamic treatment regimens. Areas covered: In this review, the authors have concisely explained doxorubicin chemotherapy and the photobiological processes of phthalocyanine triggered photodynamic therapy (PDT)...
August 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28649895/the-safety-and-efficacy-of-palbociclib-in-the-treatment-of-metastatic-breast-cancer
#19
REVIEW
Johannes Ettl, Nadia Harbeck
Palbociclib (Ibrance®) is the first-in-class CDK4/6 inhibitor which has been introduced into clinical practice for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). It is an orally administered drug, which acts by selectively inhibiting cyclin-dependant kinases CDK4 and CDK6. Given together with anti-estrogens like letrozole and fulvestrant it enhances the antiproliferative effect of these drugs without compromising the favorable toxicity profile of endocrine therapy...
August 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28649891/new-targeted-therapies-for-relapsed-pediatric-acute-lymphoblastic-leukemia
#20
REVIEW
Joanna Pierro, Laura E Hogan, Teena Bhatla, William L Carroll
The improvement in outcomes for children with acute lymphoblastic leukemia (ALL) is one of the greatest success stories of modern oncology however the prognosis for patients who relapse remains dismal. Recent discoveries by high resolution genomic technologies have characterized the biology of relapsed leukemia, most notably pathways leading to the drug resistant phenotype. These observations open the possibility of targeting such pathways to prevent and/or treat relapse. Likewise, early experiences with new immunotherapeutic approaches have shown great promise...
August 2017: Expert Review of Anticancer Therapy
journal
journal
39793
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"